OBJECTIVE: This study was conducted to determine the objective response of @entity35734 in @entity1 with advanced or recurrent @entity1822 . METHODS: Eligibility was restricted to @entity1 with measurable disease who had received no more than one prior chemotherapy regimen, who had adequate bone marrow, @entity177 , and who had recovered from previous therapy. @entity35734 was begun at 5 mg/m2/day orally for 5 days every other week, with dose modifications specified by study design. RESULTS: Of 28 @entity1 entered into the study, 27 were evaluable for @entity137 and 23 for response. Prior therapy included radiation (7 @entity1 ) and/or chemotherapy (10 @entity1 ). Measurable disease was extrapelvic in 20 cases and confined to the pelvis in 3. The overall response rate was 4.3%; there were no complete responses and 1 partial response. @entity137 were mild to moderate with no treatment-related @entity204 . @entity1503 was most common, consisting of @entity1431 (grade 1 to 2, 8 @entity1 ; grade 3 or 4, 2 @entity1 ), @entity882 (grade 1 to 2, 10 @entity1 ; grade 3 or 4, 1 @entity1 ), and @entity417 (grade 1 to 2, 6 @entity1 ; grade 3 or 4, 4 @entity1 . Severe (grade 3 or 4) nonhematologic @entity137 was uncommon: @entity390 / @entity391 /gastrointestinal (3 @entity1 ) and neurological (1 @entity1 ). Progression-free and overall survival, in months, was 2.2 (range: 0.9-13.4) and 7.2+ (range: 1.0-13.4+), respectively. CONCLUSION: Although @entity137 is acceptable, @entity35734 at this dose and schedule is ineffective therapy for @entity1 with @entity1822 . Further development of this specific regimen for this indication is unwarranted.

XXXX in the treatment of recurrent or advanced @entity1822 : a phase II study of the Gynecologic Oncology Group.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicities'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal, and hepatic function'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['Hematological toxicity'] @entity1822 :: ('MESH:D007890', 'Disease') :: ['recurrent leiomyosarcoma', 'leiomyosarcoma of the uterus'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity35734 :: ('MESH:D016597', 'Chemical') :: ['Trimetrexate', 'trimetrexate'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity35734 :: (MESH:D016597,Chemical) :: ['Trimetrexate']
